Huadong Medicine released its 2026 interim report, showing total operating revenue of 22.067 billion yuan, net profit attributable to the parent company of 1.861 billion yuan, and net cash inflow from operating activities of 2.499 billion yuan. The company's latest asset-liability ratio is 35.51 percent, ranking 66th among comparable companies that have disclosed data, up 0.88 percentage points from the previous quarter. Gross margin is 32.80 percent, ranking 88th, down 1.14 percentage points from the previous quarter and down 1.10 percentage points from the same period last year. Latest return on equity is 7.31 percent, down 0.33 percentage points from the same period last year. Diluted earnings per share is 1.06 yuan. Total asset turnover is 0.56 times, down 1.17 percent from the same period last year; inventory turnover is 2.81 times, down 3.95 percent from the same period last year. The company has 100,200 shareholders, and the top ten shareholders hold 1.177 billion shares, accounting for 67.12 percent of total share capital.
Huadong Medicine Co LtdInterim report shows revenue and profit, but no comparative expectations or market reaction; metrics mixed.
